Kris M G, Gralla R J, Kelsen D P, Casper E S, Burke M T, Fiore J J, Cibas I R, Heelan R T
Am J Clin Oncol. 1985 Oct;8(5):377-9. doi: 10.1097/00000421-198510000-00007.
4-Demethoxydaunorubicin (4-DMDR) is an orally active analog of daunorubicin that in preclinical testing has demonstrated greater antitumor activity and less cardiotoxicity than its parent compound. Thirty-two patients with metastatic non-small cell lung cancer received 4-DMDR at a dose of 40-50 mg/m2 orally every 21 days. Thirteen patients had received no prior chemotherapy. Among the 30 adequately treated patients, one major response lasting 5.2 months was observed. Leukopenia 10-14 days after treatment was the most commonly observed toxicity. With an overall observed major response rate of 3.3% in 30 patients, the predicted true response rate is less than or equal to 16% (p = 0.05). At the dose and schedule studied in this group of patients with non-small cell lung cancer, 4-DMDR had only marginal activity.
4-去甲氧基柔红霉素（4-DMDR）是柔红霉素的一种口服活性类似物，在临床前试验中已证明其比母体化合物具有更强的抗肿瘤活性和更低的心脏毒性。32例转移性非小细胞肺癌患者接受了4-DMDR治疗，剂量为40-50mg/m²，口服，每21天一次。13例患者此前未接受过化疗。在30例接受充分治疗的患者中，观察到1例主要缓解，持续5.2个月。治疗后10-14天出现白细胞减少是最常见的毒性反应。在30例患者中，总体观察到的主要缓解率为3.3%，预测的真实缓解率小于或等于16%（p = 0.05）。在这组非小细胞肺癌患者所研究的剂量和给药方案下，4-DMDR仅具有微弱活性。
